Gonorrhea Symptoms: Recognition, Testing, and Treatment

Gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae. Many infections are asymptomatic, especially in women, making screening critical.

Symptoms by Site

Urogenital — Men

  • Urethral discharge (white, yellow, green; purulent)
  • Dysuria (burning on urination)
  • Urinary frequency/urgency
  • Testicular/epididymal pain/swelling (epididymitis)

Urogenital — Women

  • Often asymptomatic
  • Increased vaginal discharge (yellow/green)
  • Dysuria
  • Intermenstrual or postcoital bleeding
  • Lower abdominal/pelvic pain (suggests PID)
  • Fever, nausea (if ascending infection)

Rectal (All Genders)

  • Often asymptomatic
  • Discharge, bleeding, pruritus, tenesmus, pain

Pharyngeal

  • Usually asymptomatic
  • Sore throat, exudates (rare)

Conjunctival (Neonatal/Adult)

  • Purulent conjunctivitis, eyelid edema — ophthalmia neonatorum in newborns

Complications of Untreated Infection

  • Women: PID, tubal factor infertility, ectopic pregnancy, chronic pelvic pain, Fitz-Hugh-Curtis syndrome (perihepatitis).
  • Men: Epididymitis, infertility, prostatitis.
  • Disseminated gonococcal infection (DGI): Arthritis-dermatitis syndrome (migratory arthralgia, tenosynovitis, pustular rash), septic arthritis, endocarditis, meningitis.
  • Neonatal: Ophthalmia, sepsis, scalp abscess.
  • HIV risk: Gonorrhea increases HIV acquisition/transmission 3–5 fold.

Diagnosis

  • NAAT (nucleic acid amplification test) on urine, urethral/cervical/vaginal/rectal/pharyngeal swabs — gold standard.
  • Culture (for antibiotic susceptibility) if treatment failure or DGI.
  • Gram stain (urethral discharge in men: gram-negative intracellular diplococci = presumptive).

Treatment (CDC 2021 Guidelines)

  • Uncomplicated urogenital/rectal/pharyngeal: Ceftriaxone 500 mg IM single dose (1 g if ≥150 kg).
  • If chlamydia not excluded: Add doxycycline 100 mg PO BID × 7 days.
  • Allergy to cephalosporins: Gentamicin 240 mg IM + azithromycin 2 g PO (single dose).
  • DGI: Ceftriaxone 1 g IV/IM q24h × 24–48h after improvement, then oral step-down.

Follow-Up

  • Test-of-cure at 7–14 days if pharyngeal infection or alternative regimen used.
  • Retest at 3 months (high reinfection rate).
  • Partner notification and treatment (expedited partner therapy where legal).
  • HIV/syphilis testing at diagnosis.

Prevention

Consistent condom use, mutual monogamy with tested partner, regular STI screening (annually for sexually active <25, or per risk), PrEP for HIV prevention does not protect against gonorrhea.

Gonorrhea - Related Articles